34m
Hosted on MSNModerna Q4 Earnings and Revenues Beat, COVID Vaccine Sales DeclineModerna MRNA incurred a loss of $2.50 per share in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of ...
A member of the U.K. Parliament is calling for regulators to audit pharmaceutical companies that have made misleading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results